CELADON PHARMACEUTICALS PLC Logo

CELADON PHARMACEUTICALS PLC

Vertically integrated pharma developing cannabis medicines for chronic pain.

CEL | IL

Overview

Corporate Details

ISIN(s):
GB00BDQYGP38
LEI:
213800YXCATORT475807
Country:
United Kingdom
Address:
32-33 COWCROSS STREET, EC1M 6DF LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celadon Pharmaceuticals PLC is a vertically integrated pharmaceutical company focused on the research, cultivation, manufacturing, and commercial sale of cannabis-based medicines. The company's primary target market is chronic pain, aiming to provide alternatives to traditional treatments. It operates a licensed, 100,000 sq ft, EU-GMP certified facility for the indoor cultivation of high-THC cannabis and the extraction of Active Pharmaceutical Ingredients (API). A key differentiator is its MHRA-conditionally approved clinical trial for chronic pain, which seeks to generate robust data for potential reimbursement by national health services. Founded in 2018, Celadon is also engaged in R&D to generate novel intellectual property and develop a pipeline of prescription medicines for various conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-28 17:10
Post-Annual General Meeting Information
Result of General Meeting
English 20.4 KB
2025-07-02 08:00
Pre-Annual General Meeting Information
Proposed Cancellation
English 99.3 KB
2025-07-01 12:48
Capital/Financing Update
Funding Update
English 10.8 KB
2025-07-01 09:20
Post-Annual General Meeting Information
Result of AGM
English 24.0 KB
2025-06-30 08:00
Report Publication Announcement
Funding and Operational Update, Delay in Results
English 22.5 KB
2025-06-11 08:00
Capital/Financing Update
New Committed Credit Facility
English 14.2 KB
2025-06-06 16:55
Regulatory News Service
Funding Update, Notice of AGM
English 12.1 KB
2025-05-30 19:07
Capital/Financing Update
Funding Update
English 11.3 KB
2025-03-19 08:00
Capital/Financing Update
Funding Update
English 11.8 KB
2025-02-26 14:00
Capital/Financing Update
New Committed Credit Facility
English 15.5 KB
2025-02-12 08:00
Capital/Financing Update
Finance Update
English 10.4 KB
2025-01-31 08:00
Capital/Financing Update
Finance Update
English 10.7 KB
2025-01-16 08:00
Regulatory News Service
Update on Strategic Collaboration
English 13.7 KB
2025-01-02 08:00
Capital/Financing Update
Funding Update
English 10.6 KB
2024-12-20 08:00
Capital/Financing Update
Finance Update
English 10.8 KB

Automate Your Workflow. Get a real-time feed of all CELADON PHARMACEUTICALS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CELADON PHARMACEUTICALS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.